43.95
Precedente Chiudi:
$44.85
Aprire:
$44.58
Volume 24 ore:
865.77K
Relative Volume:
0.71
Capitalizzazione di mercato:
$2.63B
Reddito:
-
Utile/perdita netta:
$-103.69M
Rapporto P/E:
-23.66
EPS:
-1.8579
Flusso di cassa netto:
$-70.46M
1 W Prestazione:
+2.38%
1M Prestazione:
+58.26%
6M Prestazione:
+102.25%
1 anno Prestazione:
+157.77%
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Nome
Enliven Therapeutics Inc
Settore
Industria
Telefono
720-647-8519
Indirizzo
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
ELVN
Enliven Therapeutics Inc
|
43.95 | 2.68B | 0 | -103.69M | -70.46M | -1.8579 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Iniziato | Goldman | Buy |
| 2024-12-13 | Iniziato | BTIG Research | Buy |
| 2024-09-09 | Iniziato | H.C. Wainwright | Buy |
| 2024-06-11 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-09 | Iniziato | Mizuho | Buy |
| 2023-03-29 | Iniziato | Jefferies | Buy |
Mostra tutto
Enliven Therapeutics Inc Borsa (ELVN) Ultime notizie
Enliven (ELVN) gets higher price targets from HC Wainwright and Mizuho - MSN
Enliven Therapeutics (ELVN) soars to 5-year high as analysts 'upbeat' - MSN
ELVN Earnings History & Surprises | EPS & Revenue Results | ENLIVEN THERAPEUTICS INC (NASDAQ:ELVN) - ChartMill
(ELVN) Volatility Zones as Tactical Triggers - Stock Traders Daily
ELVN Surges Amid Strategic Acquisition Talks and Analyst Upgrades - StocksToTrade
H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details - Investing.com Canada
Merck’s Acquisition Ups Competition in Pharmaceuticals, Enliven Shines - timothysykes.com
Merck’s Acquisition Sparks Surge in Enliven Therapeutics - StocksToTrade
Enliven Therapeutics Regains Attention as Stock Prices Soar - timothysykes.com
Enliven Therapeutics stock hits 52-week high at $40.66 - Investing.com
Enliven Therapeutics stock hits 52-week high at $40.66 By Investing.com - Investing.com South Africa
Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and Mizuho - Insider Monkey
Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio - MSN
5 Best Performing Stocks of Q1 2026 to Watch for Q2 - Insider Monkey
Enliven Therapeutics stock hits 52-week high at 30.29 USD - Investing.com
25,000-share resale via Jefferies — Enliven Therapeutics (NASDAQ: ELVN) - Stock Titan
[144] Enliven Therapeutics, Inc. SEC Filing - Stock Titan
Q1 EPS Estimate for Enliven Therapeutics Reduced by Analyst - MarketBeat
Assessing Enliven Therapeutics (ELVN) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Price-Driven Insight from (ELVN) for Rule-Based Strategy - Stock Traders Daily
Enliven Therapeutics CMO Executes $1.2M Stock Sale | Company Update 2026News and Statistics - IndexBox
Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million - AOL.com
Volume Report: Should I trade or invest in Enliven Therapeutics Inc2026 Market WrapUp & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Enliven Therapeutics Insider Sold Shares Worth $1,404,024, According to a Recent SEC Filing - MarketScreener
Enliven (NASDAQ: ELVN) CMO exercises options and sells 40K shares - Stock Titan
Aug PreEarnings: Can Enliven Therapeutics Inc disrupt its industryDip Buying & Low Volatility Stock Recommendations - baoquankhu1.vn
Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $56.00 at HC Wainwright - Defense World
ELVN Stock Soars as Merck’s Billion-Dollar Acquisition Validates Strategy - timothysykes.com
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Terns Pharmaceuticals (TERN) - The Globe and Mail
Enliven Therapeutics (NASDAQ:ELVN) Given New $56.00 Price Target at HC Wainwright - MarketBeat
Enliven Therapeutics stock price target raised to $56 by H.C. Wainwright - Investing.com Canada
Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High on Analyst Upgrade - MarketBeat
Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts ‘Upbeat’ - Insider Monkey
Enliven Reports Q4 Loss; Clinical Milestones Ahead - timothysykes.com
Enliven Therapeutics (ELVN) affiliate files to sell 45,000 shares via Jefferies - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up After Analyst Upgrade - marketbeat.com
Enliven Therapeutics (NASDAQ:ELVN) Gains Attention After Price Target Adjustment - kalkinemedia.com
Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $45.00 - MarketBeat
Clear Street reiterates Enliven Therapeutics stock Buy on CML opportunity By Investing.com - ca.investing.com
Enliven Therapeutics stock surges 28% on Merck-Terns deal By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
ELVN Surges 12%: Clinical Milestone Breaks Barriers and Sparks Biotech Momentum - Bitget
Mizuho raises Enliven Therapeutics price target to $45 on CML data - Investing.com Canada
Enliven Therapeutics (Nasdaq: ELVN) founder files Form 144 to sell 100,000 - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month HighShould You Buy? - MarketBeat
Enliven Therapeutics stock hits 52-week high at $30.98 By Investing.com - Investing.com Canada
Enliven Therapeutics Inc Azioni (ELVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):